SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Shilpa Medicare - Quaterly Results

23 May 2022 Evaluate
The sales for the March 2022 quarter moved up 30.42% to Rs. 728.73 millions as compared to Rs. 558.74 millions during the corresponding quarter last year.The Net Loss for the quarter ended March 2022 is Rs. -29.47 millions as compared to Net Profit of Rs. 100.08 millions of corresponding quarter ended March 2021Operating Profit reported a sharp decline to 87.89 millions from 238.49 millions in the corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202203 202103 % Var 202203 202103 % Var 202203 202103 % Var
Sales 728.73 558.74 30.42 3569.52 2570.50 38.86 3569.52 2570.50 38.86
Other Income 103.36 313.32 -67.01 408.62 322.46 26.72 408.62 322.46 26.72
PBIDT 87.89 238.49 -63.15 625.49 656.16 -4.67 625.49 656.16 -4.67
Interest 17.32 16.19 6.98 90.54 60.74 49.06 90.54 60.74 49.06
PBDT 69.57 222.30 -68.70 623.04 1124.90 -44.61 623.04 1124.90 -44.61
Depreciation 102.92 67.31 52.90 348.18 222.81 56.27 348.18 222.81 56.27
PBT -33.35 154.99 -121.52 274.86 902.09 -69.53 274.86 902.09 -69.53
TAX -3.88 54.91 -107.07 73.27 251.17 -70.83 73.27 251.17 -70.83
Deferred Tax 1.94 27.62 -92.98 25.25 93.37 -72.96 25.25 93.37 -72.96
PAT -29.47 100.08 -129.45 201.59 650.92 -69.03 201.59 650.92 -69.03
Equity 86.80 81.53 6.46 86.80 81.53 6.46 86.80 81.53 6.46
PBIDTM(%) 12.06 42.68 -71.74 17.52 25.53 -31.35 17.52 25.53 -31.35

Shilpa Medicare Share Price

411.55 0.30 (0.07%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×